Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Rosa S. Schneiderman"'
Autor:
Dietmar Krex, Paula Bartmann, Doris Lachmann, Alexander Hagstotz, Willi Jugel, Rosa S. Schneiderman, Karnit Gotlib, Yaara Porat, Katja Robel, Achim Temme, Moshe Giladi, Susanne Michen
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 5, p 5016 (2023)
Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an
Externí odkaz:
https://doaj.org/article/9ce63a658580400690c19831545b7531
Autor:
Moshe Giladi, Mijal Munster, Rosa S. Schneiderman, Tali Voloshin, Yaara Porat, Roni Blat, Katarzyna Zielinska-Chomej, Petra Hååg, Ze’ev Bomzon, Eilon D. Kirson, Uri Weinberg, Kristina Viktorsson, Rolf Lewensohn, Yoram Palti
Publikováno v:
Radiation Oncology, Vol 12, Iss 1, Pp 1-13 (2017)
Abstract Background Tumor Treating Fields (TTFields) are an anti-neoplastic treatment modality delivered via application of alternating electric fields using insulated transducer arrays placed directly on the skin in the region surrounding the tumor.
Externí odkaz:
https://doaj.org/article/8441333577d849efba129827b7363495
Autor:
Tali Voloshin, Mijal Munster, Yuval Shmueli, Uri Weinberg, Adi Haber, Anna Shteingauz, Helena Mumblat, Shiri Davidi, Shiri Danilov, Moshe Giladi, Einav Zeevi, Yoram Palti, Antonia Martinez-Conde, Adrian Kinzel, Catherine Tempel-Brami, Yaara Porat, Eyal Dor-On, Ori Braten, Carolina Lajterer, Rosa S. Schneiderman, Roni Blatt
Publikováno v:
Lung Cancer. 160:99-110
Objectives Tumor Treating Fields (TTFields) are low intensity, intermediate frequency, alternating electric fields with antimitotic effects on cancerous cells. TTFields concomitant with pemetrexed and a platinum agent are approved in the US and EU as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f4ed745c65ea1f000e412d10635e98
https://doi.org/10.1016/j.lungcan.2021.08.011
https://doi.org/10.1016/j.lungcan.2021.08.011
Autor:
Shay Cahal, Yaara Porat, Moshe Giladi, Eilon D. Kirson, A. Shteingauz, Adrian Kinzel, Aviran Itzhaki, Einav Zeevi, Uri Weinberg, Tali Voloshin, Yoram Palti, Catherine Tempel Brami, Mijal Munster, Noa Kaynan, Shiri Davidi, Rosa S. Schneiderman, Roni Blat
Publikováno v:
Cancer Immunology, Immunotherapy
Tumor-treating fields (TTFields) are alternating electric fields in a specific frequency range (100–300 kHz) delivered to the human body through transducer arrays. In this study, we evaluated whether TTFields-mediated cell death can elicit antitumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9715fe0f2ba8490d0c2aedea5d2f136b
https://doi.org/10.1007/s00262-020-02534-7
https://doi.org/10.1007/s00262-020-02534-7
Autor:
Tali Voloshin, A. Shteingauz, Mijal Munster, A. Haber, Uri Weinberg, Karnit Gotlib, S. Jacobovitch, Yoram Palti, Shiri Davidi, Adrian Kinzel, E. Dor-On, Einav Zeevi, Rosa S. Schneiderman, C. Tempel Brami, Moshe Giladi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e47-e48
Purpose/Objective(s) Hepatocellular carcinoma (HCC) is a highly malignant liver cancer and is one of the leading causes of cancer-related mortality worldwide. Sorafenib, a multikinase inhibitor, is the main first-line treatment for advanced HCC, yet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48d2dda638cc4d9fe781df48eff58cf7
https://doi.org/10.1016/j.ijrobp.2021.07.378
https://doi.org/10.1016/j.ijrobp.2021.07.378
Autor:
A. Martinez-Conde, A. Haber, S. Danilov, Uri Weinberg, C. Lajterer, C. Tempel-Brami, Y. Shmueli, Yaara Porat, Rosa S. Schneiderman, O. Braten, Yoram Palti, A. Shteingauz, R. Blatt, Shiri Davidi, Moshe Giladi, H. Mumblat, E. Dor-On, Einav Zeevi, Tali Voloshin, Adrian Kinzel, Mijal Munster
Publikováno v:
Journal of Thoracic Oncology. 16:S956-S957
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4556b76594f03bec61512c101b541a87
https://doi.org/10.1016/j.jtho.2021.08.229
https://doi.org/10.1016/j.jtho.2021.08.229
Autor:
Moshe Giladi, E. Dor-On, Einav Zeevi, Mijal Munster, Rosa S. Schneiderman, A. Shteingauz, C. Tempel-Brami, T. Voloshin, A. Haber, S. Jacobovitch, Shiri Davidi
Publikováno v:
Annals of Oncology. 32:S162-S163
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1937521bbb7f426a4d60748843da4195
https://doi.org/10.1016/j.annonc.2021.05.239
https://doi.org/10.1016/j.annonc.2021.05.239
Autor:
Wyatt Potter, Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Catherine Tempel-Brami, Einav Zeevi, Eyal Dor-On, Rosa S Schneiderman, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Publikováno v:
Journal of Clinical Oncology. 40:464-464
464 Background: Hepatocellular carcinoma (HCC) is a highly malignant liver cancer and a leading cause of cancer related mortality. Sorafenib was the first approved systemic treatment for HCC, and remains one of few front-line treatments for this mali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1dc66c3465ec34e3862bb9f57acceb84
https://doi.org/10.1200/jco.2022.40.4_suppl.464
https://doi.org/10.1200/jco.2022.40.4_suppl.464
Autor:
Uri Weinberg, A. Haber, O. Braten, Yoram Palti, Tali Voloshin, C. Tempel Brami, R. Blatt, E. Dor-On, Y. Shmueli, Einav Zeevi, A. Shteingauz, H. Mumblat, A. Martinez-Conde, Shiri Davidi, C. Lajterer, S. Danilov, Moshe Giladi, Rosa S. Schneiderman, Mijal Munster, Yaara Porat
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e463
Purpose/Objective(s) Tumor Treating Fields (TTFields) are low intensity (1-3 V/cm), intermediate frequency (100-500 kHz), alternating electric fields delivered to solid tumors noninvasively and locoregionally. TTFields have demonstrated a promising m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5412af805d1a0519c4502999b6e756b6
https://doi.org/10.1016/j.ijrobp.2021.07.1297
https://doi.org/10.1016/j.ijrobp.2021.07.1297
Autor:
Uri Weinberg, Helena Mumblat, Yoram Palti, Ori Braten, Antonia Martinez, Anna Shteingauz, Roni Blatt, Catherine Tempel-Brami, Eyal Dor-On, Adi Haber, Shiri Danilov, Moshe Giladi, Shiri Davidi, Adrian Kinzel, Yaara Porat, Tali Voloshin, Mijal Munster, Yuval Shmueli, Einav Zeevi, Carolina Lajterer, Rosa S. Schneiderman
Publikováno v:
Cancer Research. 81:1186-1186
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer with a poor prognosis and limited treatment options. Tumor Treating Fields (TTFields) are a noninvasive, locoregionally, antineoplastic treatment, delivering low inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be9e54918abfca401ab94577e9d9a32
https://doi.org/10.1158/1538-7445.am2021-1186
https://doi.org/10.1158/1538-7445.am2021-1186